SI1071745T1 - Process for synthesizing cox-2 inhibitors - Google Patents

Process for synthesizing cox-2 inhibitors

Info

Publication number
SI1071745T1
SI1071745T1 SI9930632T SI9930632T SI1071745T1 SI 1071745 T1 SI1071745 T1 SI 1071745T1 SI 9930632 T SI9930632 T SI 9930632T SI 9930632 T SI9930632 T SI 9930632T SI 1071745 T1 SI1071745 T1 SI 1071745T1
Authority
SI
Slovenia
Prior art keywords
inhibitors
cox
synthesizing
synthesizing cox
Prior art date
Application number
SI9930632T
Other languages
English (en)
Slovenian (sl)
Inventor
Edward G. Corley
Ian W. Davies
Robert D. Larsen
Philip J. Pye
Kai Rossen
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Publication of SI1071745T1 publication Critical patent/SI1071745T1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61Halogen atoms or nitro radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/02Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
    • C07C251/30Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having nitrogen atoms of imino groups quaternised

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SI9930632T 1998-04-24 1999-04-20 Process for synthesizing cox-2 inhibitors SI1071745T1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8288898P 1998-04-24 1998-04-24
US8566898P 1998-05-15 1998-05-15
PCT/US1999/008645 WO1999055830A2 (en) 1998-04-24 1999-04-20 Process for synthesizing cox-2 inhibitors
EP99918706A EP1071745B1 (en) 1998-04-24 1999-04-20 Process for synthesizing cox-2 inhibitors

Publications (1)

Publication Number Publication Date
SI1071745T1 true SI1071745T1 (en) 2004-10-31

Family

ID=26767964

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9930632T SI1071745T1 (en) 1998-04-24 1999-04-20 Process for synthesizing cox-2 inhibitors

Country Status (28)

Country Link
US (2) US6040319A (cs)
EP (1) EP1071745B1 (cs)
JP (2) JP3325264B2 (cs)
KR (1) KR100414998B1 (cs)
CN (1) CN1178658C (cs)
AR (1) AR015279A1 (cs)
AT (1) ATE272613T1 (cs)
AU (1) AU759469B2 (cs)
BR (2) BRPI9917739B8 (cs)
CA (1) CA2329193C (cs)
CZ (1) CZ292515B6 (cs)
DE (1) DE69919151T2 (cs)
DK (1) DK1071745T3 (cs)
EA (1) EA002975B1 (cs)
ES (1) ES2226378T3 (cs)
HK (1) HK1031399A1 (cs)
HR (1) HRP20000722B1 (cs)
HU (1) HU227627B1 (cs)
IL (2) IL139127A0 (cs)
NZ (1) NZ507597A (cs)
PL (1) PL193248B1 (cs)
PT (1) PT1071745E (cs)
RS (1) RS49945B (cs)
SI (1) SI1071745T1 (cs)
SK (1) SK284805B6 (cs)
TW (1) TW474934B (cs)
UA (1) UA57143C2 (cs)
WO (1) WO1999055830A2 (cs)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861419A (en) 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
MXPA01007169A (es) 1999-01-14 2003-06-06 Lonza Ag 1-(6-metilpiridin-3-il)-2-(4-(metilsulfonil)fenil)etanona y metodo para su elaboracion.
SK284903B6 (sk) * 1999-01-14 2006-02-02 Lonza Ag Spôsob výroby 1-(6-metylpyridín-3-yl)-2-[(4- (metylsulfonyl)fenyl]etanónu a medziprodukty
JP2001115963A (ja) 1999-10-13 2001-04-27 Daikin Ind Ltd 圧縮機
AU776544B2 (en) 1999-11-29 2004-09-16 Merck Canada Inc. Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-(2,3') bipyridinyl
US6858631B1 (en) 1999-11-29 2005-02-22 Merck & Co., Inc. Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl
ATE283048T1 (de) * 1999-12-08 2004-12-15 Pharmacia Corp Cyclooxygenase-2 hemmer enthaltende zusammensetzungen mit schnellem wirkungseintritt
JP2001261653A (ja) * 2000-03-17 2001-09-26 Sankio Chemical Co Ltd ピリジン誘導体の合成法
US6521642B2 (en) 2000-05-26 2003-02-18 Merck & Co., Inc. 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl in pure crystalline form and process for synthesis
PH12001001175B1 (en) * 2000-05-26 2006-08-10 Merck Sharp & Dohme 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- (2,3')bipyridinyl in pure crystalline form and process for synthesis
US6800647B2 (en) 2000-05-26 2004-10-05 Merck & Co., Inc. 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3]bipyridinyl in pure crystalline form and process for synthesis
CA2414674A1 (en) * 2000-07-13 2002-01-24 Pharmacia Corporation Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
US7695736B2 (en) 2001-04-03 2010-04-13 Pfizer Inc. Reconstitutable parenteral composition
US20040132780A1 (en) * 2001-05-04 2004-07-08 Allen Christopher P. Method and compositions for treating migraines
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
JP4700916B2 (ja) 2004-02-02 2011-06-15 富士フイルムファインケミカルズ株式会社 ピリジン誘導体の製造方法
US7271383B2 (en) * 2004-08-11 2007-09-18 Lexmark International, Inc. Scanning system with feedback for a MEMS oscillating scanner
WO2006137839A2 (en) 2004-08-24 2006-12-28 Merck & Co., Inc. Combination therapy for treating cyclooxygenase-2 mediated diseases or conditions in patients at risk of thrombotic cardiovascular events
JP2010516679A (ja) * 2007-01-19 2010-05-20 マリンクロット インコーポレイテッド 診断用および治療用シクロオキシゲナーゼ−2結合リガンド
PL2401253T3 (pl) 2009-02-27 2016-05-31 Cadila Healthcare Ltd Sposób otrzymywania etorykoksybu
ES2683125T3 (es) 2010-06-16 2018-09-25 Glenmark Generics Limited Proceso para la preparación de piridinas 2,3-diaril-5-sustituidas y sus compuestos intermedios
US8841457B2 (en) 2010-11-15 2014-09-23 Virdev Intermediates Pvt. Ltd. Process for cyclooxygenase-2 selective inhibitor
ITMI20110362A1 (it) * 2011-03-09 2012-09-10 F I S Fabbrica Italiana Sint P A Procedimento per la preparazione di 1-(6-metilpiridin-3-il)-2-[4-(metilsolfonil)fenil]etanone, un intermedio dell'etoricoxib.
WO2012163839A1 (en) 2011-05-27 2012-12-06 Farma Grs, D.O.O. A process for the preparation of polymorphic form i of etoricoxib
ITMI20111455A1 (it) 2011-07-29 2013-01-30 Italiana Sint Spa Nuovo procedimento per la preparazione di 1-(6-metilpiridin-3-il)-2-[4-(metilsolfonil)fenil]etanone, un intermedio dell'etoricoxib.
CN103204803A (zh) 2012-01-13 2013-07-17 阿尔弗雷德·E·蒂芬巴赫尔有限责任两合公司 用于合成依托考昔的方法
ITMI20120394A1 (it) 2012-03-14 2013-09-15 Zach System Spa Processo di sintesi di un chetosolfone derivato
EP2831045A2 (en) 2012-03-30 2015-02-04 Mylan Laboratories, Limited An improved process for the preparation of etoricoxib
GR1007973B (el) * 2012-06-26 2013-09-12 Φαρματεν Αβεε, Νεα ν-οξοιμινο παραγωγα ως ενδιαμεσα μιας βελτιωμενης μεθοδου παρασκευης 2,3-διαρυλο-5-υποκατεστημενων πυριδινων
ES2630051T3 (es) 2012-08-27 2017-08-17 Cadila Healthcare Limited Composición farmacéutica de etoricoxib
ITVI20130014A1 (it) 2013-01-22 2014-07-23 Italiana Sint Spa Procedimento molto efficiente per preparare un intermedio di etoricoxib
WO2014114352A1 (en) * 2013-01-25 2014-07-31 Synthon Bv Process for making etoricoxib
CN104418799A (zh) * 2013-09-03 2015-03-18 天津药物研究院 一种依托考昔的晶型及其制备方法和应用
WO2015036550A1 (en) 2013-09-13 2015-03-19 Synthon B.V. Process for making etoricoxib
US10500178B2 (en) 2015-03-13 2019-12-10 The Board Of Trustees Of The Leland Stanford Junior University LTB4 inhibition to prevent and treat human lymphedema
CN104817473A (zh) * 2015-03-27 2015-08-05 南京大学 1-二甲氨基-3-二甲亚胺基-2-氯丙烯高氯酸盐在制备依托考昔中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA988522A (en) * 1972-05-05 1976-05-04 Haydn W.R. Williams 1,8-naphthyridine compounds
DE3842062A1 (de) * 1988-12-14 1990-06-28 Hoechst Ag Explosionssichere 1-dimethylamino-3-dimethylimino-2-arylpropen-1-salze, verfahren zu ihrer herstellung und ihre verwendung
US5861419A (en) * 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
AU723179B2 (en) * 1996-07-18 2000-08-17 Merck Canada Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors

Also Published As

Publication number Publication date
HU227627B1 (en) 2011-10-28
DE69919151T2 (de) 2005-07-28
JP3834263B2 (ja) 2006-10-18
WO1999055830A2 (en) 1999-11-04
CZ20003940A3 (en) 2001-06-13
YU64100A (sh) 2002-11-15
CN1306425A (zh) 2001-08-01
HRP20000722A2 (en) 2001-06-30
BRPI9917739B1 (pt) 2016-05-03
KR100414998B1 (ko) 2004-01-13
RS49945B (sr) 2008-09-29
AU3655799A (en) 1999-11-16
CA2329193C (en) 2007-01-23
JP2002513035A (ja) 2002-05-08
HK1031399A1 (en) 2001-06-15
TW474934B (en) 2002-02-01
IL139127A (en) 2006-07-05
UA57143C2 (uk) 2003-06-16
PL344108A1 (en) 2001-09-24
WO1999055830A3 (en) 1999-12-29
EP1071745A4 (en) 2002-05-15
KR20010042941A (ko) 2001-05-25
ATE272613T1 (de) 2004-08-15
EA200001102A1 (ru) 2001-04-23
SK284805B6 (sk) 2005-11-03
CZ292515B6 (cs) 2003-10-15
IL139127A0 (en) 2001-11-25
AR015279A1 (es) 2001-04-18
PL193248B1 (pl) 2007-01-31
CN1178658C (zh) 2004-12-08
CA2329193A1 (en) 1999-11-04
NZ507597A (en) 2004-02-27
BR9909844A (pt) 2001-04-03
AU759469B2 (en) 2003-04-17
US6252116B1 (en) 2001-06-26
EA002975B1 (ru) 2002-12-26
EP1071745A2 (en) 2001-01-31
HRP20000722B1 (en) 2009-07-31
DK1071745T3 (da) 2004-11-29
DE69919151D1 (de) 2004-09-09
SK15892000A3 (sk) 2001-07-10
HUP0101407A3 (en) 2002-12-28
US6040319A (en) 2000-03-21
JP3325264B2 (ja) 2002-09-17
EP1071745B1 (en) 2004-08-04
HUP0101407A2 (hu) 2001-09-28
JP2003040852A (ja) 2003-02-13
PT1071745E (pt) 2004-11-30
ES2226378T3 (es) 2005-03-16
BRPI9917739B8 (pt) 2021-05-25
BR9909844B1 (pt) 2010-10-19

Similar Documents

Publication Publication Date Title
PL344108A1 (en) Process for synthesizing cox-2 inhibitors
AU2792499A (en) Improved methods for synthesis of oligonucleotides
PL342469A1 (en) Method of obtaining stilbenic compounds
SI0970917T1 (sl) Postopek za pripravo prevlecenih perkisikovih spojin
AU3077699A (en) Apparatus for performing hippotherapy
IL138821A (en) Method for unambigous range estimation
IL149446A0 (en) Method for synthesizing nucleic acid
AU5660399A (en) An apparatus for performing animal related operations
GB9819417D0 (en) Reaction method
AU3444899A (en) Method for the rapid determination of bacteria
HUP0003155A3 (en) Process for making 2-aryl-3-aryl-5-halo pyridines useful as cox-2 inhibitors
EP1059760A4 (en) BLOCK ENCRYPTION OF DISCRETE DATA
GB9805028D0 (en) Photobioreactor apparatus
HU9902691D0 (en) Process for re-esterification of alfa-keto-carboxylic-acid-esters
AU1810399A (en) Method for synthesizing
HUP0102016A3 (en) Method for copperplating substrates
HUP0103002A3 (en) New process for obtaining 17betha-(n-terc-butylcarbamoyl)-3-one-4-aza-steroids
GB9823420D0 (en) Process for making phenyl heterocylces useful as cox-2 inhibitors
IL138413A0 (en) Method for the biotechnological oxidation of substituted trimethylcyclohexenyl compounds
HUP0103105A3 (en) Process for the synthesis of exochelins
HUP0103672A3 (en) Process for preparation of exochelins
AU5541199A (en) An apparatus for performing animal related operations
GB2337992B (en) Method for labelling of oligonucleotides
GB9709686D0 (en) Process for making 2-aryl-3-aryl-5-halo pyridines useful as cox-2 inhibitors
GB9806691D0 (en) Process for making phenyl heterocycles useful as cox-2 inhibitors